Gentler chemo tested for elderly lymphoma patients
NCT ID NCT04594798
Summary
This study is testing a modified, potentially less harsh chemotherapy combination for patients aged 75 and older with an aggressive type of blood cancer called DLBCL. The goal is to see if adding a targeted drug (polatuzumab vedotin) to a reduced-dose standard regimen is effective and safe for this older, often frailer population. Researchers will measure how long patients live without their cancer getting worse and their overall survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, B-CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Rochester
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.